Skip to main content
    A

    Avalo Therapeutics Inc (AVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.13
    -0.24 (-3.26%)

    Market Cap: $448.71M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Avalo Therapeutics Inc (AVTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Avalo Therapeutics (AVTX) has a market cap of $448.71M and an enterprise value of $383.72M. It kept -150259.32% of revenue as net income over the last 12 months. Its share count is up 293.28% from a year earlier.

    Total Valuation

    Enterprise value is 14.48% below the market cap, as cash exceeds debt.

    Market Cap$448.71M
    Enterprise Value$383.72M
    Latest price (Nov 17, 2026)$7.13

    Key Dates

    The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 22, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 26.28% in the quarter ended Sep 30, 2026 and grew 215.08% a year over 2 years.

    Shares Outstanding55.06M
    Shares Change (YoY)+293.28%
    Shares Change (QoQ)+26.28%
    Share Count Growth (2Y CAGR)+215.08%

    Valuation Ratios

    P/B Ratio0.9x
    P/TBV Ratio0.9x

    Price Statistics

    The stock is down 52.81% over 52 weeks and trades 39.78% below its 50-day average.

    Beta (1Y)1.57
    52-Week Change-52.81%
    1-Month Change-38.48%
    3-Month Change-65.64%
    6-Month Change-56.18%
    5-Year Change-99.89%
    10-Year Change-99.93%
    Total Return (1Y)-52.81%
    Total Return (3Y CAGR)-30.88%
    Total Return (5Y CAGR)-74.19%
    Return vs SPY (1Y)-71.95%
    Max Drawdown (1Y)-71.01%
    Max Drawdown (3Y)-83.62%
    Sharpe Ratio (1Y)-0.99
    Correlation with SPY (1Y)0.23
    50-Day Average$11.84
    200-Day Average$15.54
    52-Week Range$6.53 to $24.27
    RSI (14 Days)34.7
    Average Volume (20 Days)3.35M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 16.63x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio16.63x
    Quick Ratio16.63x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -20.31% and return on assets is -18.41% over the last 12 months.

    Return on Equity (ROE)-20.31%
    Return on Assets (ROA)-18.41%
    ROA (5Y Average)-94.16%
    Asset Turnover0.00x

    Scores

    AVTX has an Altman Z-Score of 4.00, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score4.00
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $59.00K over the last 12 months is down 69.27% from the 12 months before.

    Revenue$59.00K
    Revenue Growth (YoY)-69.27%
    Gross Profit$59.00K
    Operating Income-$95.56M
    Pretax Income-$88.49M
    Net Income-$88.65M
    Reported EPS (TTM)-$2.52

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 90.68% of the $481.43M in total assets.

    Cash and Equivalents$64.99M
    Total Debt$0
    Net Cash$64.99M
    Net Cash Per Share$1.18
    Working Capital$376.64M
    Shareholder Equity$436.55M
    Book Value Per Share$7.93
    Tangible Book Value$426.04M
    Tangible Book Per Share$7.74
    Total Assets$481.43M
    Total Liabilities$44.88M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$63.47M
    FCF Per Share-$1.18
    Depreciation and Amortization$1.50M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -161961.02%.

    Gross Margin100.00%
    Operating Margin-161961.02%
    Pretax Margin-149976.27%
    Net Margin-150259.32%
    Gross Margin (5Y Average)93.92%

    Growth

    Revenue fell 85.16% a year over 3 years.

    Revenue Growth (3Y CAGR)-85.16%
    Revenue Growth (5Y CAGR)-61.19%
    Book Value Per Share Growth (2Y CAGR)-29.83%

    Revenue and profit by year

    Dividends and Yields

    AVTX does not pay a dividend.

    Buyback Yield-3.76%
    Shareholder Yield-3.76%

    Stock Splits

    The last split was a 1-for-238 reverse split on Dec 29, 2023.

    Last Split DateDec 29, 2023
    Split TypeReverse split
    Split Ratio1:238

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About AVTX

    What is AVTX's market cap?

    Avalo Therapeutics has a market cap of $448.71M. Its enterprise value, which adds debt and subtracts cash, is $383.72M.

    How many shares of AVTX are outstanding?

    Avalo Therapeutics has 55.06M shares outstanding. The count is up 293.28% from a year earlier.

    Does AVTX pay a dividend?

    No. Avalo Therapeutics does not pay a dividend.

    How much debt does AVTX have?

    Avalo Therapeutics has $0 of total debt and $64.99M of cash and equivalents, a net cash position of $64.99M.